These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 22735371)

  • 1. [The long-term treatment of schizophrenia].
    Herold R
    Orv Hetil; 2012 Jul; 153(26):1007-12. PubMed ID: 22735371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of treatments that can ameliorate nonadherence in patients with schizophrenia.
    Kane JM
    J Clin Psychiatry; 2006; 67 Suppl 5():9-14. PubMed ID: 16822091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rationale for the use of long-acting injectable risperidone: a survey of French psychiatrists].
    Misdrahi D; Delgado A; Bouju S; Comet D; Chiariny JF
    Encephale; 2013 May; 39 Suppl 1():S8-14. PubMed ID: 23541914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice].
    Sümegi A; Kálmán J; Csekey L
    Neuropsychopharmacol Hung; 2013 Jun; 15(2):105-17. PubMed ID: 23817361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia.
    Johnson DA
    J Clin Psychiatry; 1984 May; 45(5 Pt 2):13-21. PubMed ID: 6143743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using Long-Acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia.
    Correll CU; Lauriello J
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32609958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use.
    Burton SC
    J Psychiatr Pract; 2005 Nov; 11(6):369-78. PubMed ID: 16304505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Thwin SS; Fiore L; Valley D; Huang GD; Neal C; Vertrees JE; Liang MH;
    Clin Trials; 2011 Apr; 8(2):196-204. PubMed ID: 21270143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjunctive psychosocial therapies for the treatment of schizophrenia.
    Patterson TL; Leeuwenkamp OR
    Schizophr Res; 2008 Mar; 100(1-3):108-19. PubMed ID: 18226500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting injectable formulations of antipsychotic drugs for the treatment of schizophrenia.
    Park EJ; Amatya S; Kim MS; Park JH; Seol E; Lee H; Shin YH; Na DH
    Arch Pharm Res; 2013 Jun; 36(6):651-9. PubMed ID: 23543652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse prevention and recovery in the treatment of schizophrenia.
    Schooler NR
    J Clin Psychiatry; 2006; 67 Suppl 5():19-23. PubMed ID: 16822093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Longterm therapy of schizophrenia].
    Pajonk FG; Wobrock T; Falkai P
    Fortschr Neurol Psychiatr; 2005 Mar; 73(3):161-74; quiz 175-7. PubMed ID: 15747226
    [No Abstract]   [Full Text] [Related]  

  • 13. Long-Acting Injectable Risperidone for Relapse Prevention and Control of Breakthrough Symptoms After a Recent First Episode of Schizophrenia. A Randomized Clinical Trial.
    Subotnik KL; Casaus LR; Ventura J; Luo JS; Hellemann GS; Gretchen-Doorly D; Marder S; Nuechterlein KH
    JAMA Psychiatry; 2015 Aug; 72(8):822-9. PubMed ID: 26107752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of long-acting injectable risperidone versus oral antipsychotics in the treatment of recent-onset schizophrenia: a case-control study.
    Barrio P; Batalla A; Castellví P; Hidalgo D; García M; Ortiz A; Grande I; Pons A; Parellada E
    Int Clin Psychopharmacol; 2013 Jul; 28(4):164-70. PubMed ID: 23587986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting risperidone and oral antipsychotics in unstable schizophrenia.
    Rosenheck RA; Krystal JH; Lew R; Barnett PG; Fiore L; Valley D; Thwin SS; Vertrees JE; Liang MH;
    N Engl J Med; 2011 Mar; 364(9):842-51. PubMed ID: 21366475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relapse and therapeutic interventions in a 1-year observational cohort study of nonadherent outpatients with schizophrenia.
    Ciudad A; San L; Bernardo M; Olivares JM; Polavieja P; Valladares A; Gilaberte I
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):245-50. PubMed ID: 22056291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orally disintegrating antipsychotics may promote compliance and adherence in patients with schizophrenia.
    Tornatore FL
    J Clin Psychiatry; 2005 Nov; 66(11):1493-4; author reply 1494. PubMed ID: 16420093
    [No Abstract]   [Full Text] [Related]  

  • 18. [Maintenance pharmacotherapy of schizophrenia: remission and the effectiveness of long-acting risperidone therapy].
    Sárosi A
    Neuropsychopharmacol Hung; 2006 Dec; 8(4):179-87. PubMed ID: 17211053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose response of prophylactic antipsychotics.
    Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
    J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.